ethyl 4-bromo-3-oxohexanoate | 52851-15-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 4-bromo-3-oxohexanoate
• CAS: 52851-15-7
• 化学式: C₈H₁₃BrO₃
• 分子量: 237.093
• InChiKey: NUJFFRSXUKQHPG-UHFFFAOYSA-N

物化性质

• 沸点：
  260.7±15.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 4-bromo-3-oxohexanoate 在 水 、 lithium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 2-(6-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)acetic acid
  参考文献：
  名称：

  Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

  摘要：

  A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

  DOI：

  10.1021/jm5003606
• 作为产物：
  描述：

  丁酰乙酸乙酯 在 溴 作用下， 生成 ethyl 4-bromo-3-oxohexanoate
  参考文献：
  名称：

  天然存在的内酯和内酰胺-V：卤代β-酮酯作为合成四氢代酸的起始原料

  摘要：

  为了改善和简化合成四氢萘甲酸的合成途径，研究了15种不同取代的β-酮酯作为潜在的原料。将β-酮酸酯溴化并用2·5 N KOH作为环化剂环化。获得了Tetronic酸和七种衍生物，包括天然存在的卡罗琳酸。在许多情况下，都分离了由Favorskii重排产生的产品。讨论了NMR光谱数据。

  DOI：

  10.1016/0040-4020(73)80266-2

文献信息

• Substituted oxazoles and thiazoles derivatives as hPPAR&ggr; and hPPAR&agr; activators
  申请人：SmithKline Beecham Corporation

  公开号：US06498174B1

  公开（公告）日：2002-12-24

  The present invention discloses compounds of formula (I), and tautomeric forms, pharmaceutically acceptable salts, or solvates thereof. Preferably, the compounds of the invention are dual activators of hPPAR&ggr; and hPPARacute over (&agr;)}.

  本发明揭示了化合物的结构公式(I)，以及其互变异构体形式、药学上可接受的盐或溶剂。优选，本发明的化合物是hPPAR&ggr;和hPPARacute over (&agr;)}的双激活剂。
• Naturally occuring lactones and lactames—V
  作者：A. Svendsen、P.M. Boll

  DOI：10.1016/0040-4020(73)80266-2

  日期：1973.12

  β-keto esters were investigated as potential starting materials. The β-keto esters were brominated and cyclised with 2·5 N KOH as cyclising agent. Tetronic acid and seven derivatives including the naturally occuring carolinic acid were obtained. In a number of cases products arising from a Favorskii rearrangment were isolated. The NMR spectroscopic data are discussed.

  为了改善和简化合成四氢萘甲酸的合成途径，研究了15种不同取代的β-酮酯作为潜在的原料。将β-酮酸酯溴化并用2·5 N KOH作为环化剂环化。获得了Tetronic酸和七种衍生物，包括天然存在的卡罗琳酸。在许多情况下，都分离了由Favorskii重排产生的产品。讨论了NMR光谱数据。
• Iodine catalyzed one-pot four component synthesis of coumarinyl phosphoramidates <i>via</i> sequential addition of reactants
  作者：Mohammed Imrankhan、Kalegowda Shivashankar

  DOI：10.1039/d0nj04445h

  日期：——

  unprecedented synthetic route for the preparation of library of novel coumarinyl phosphoramidate derivatives via iodine catalysed one-pot four component reactions of 4-bromoethylacetoacetate, sodium azide, trialkyl phosphites, and phenols in ethanol solvent is reported here. The reaction proceeds via nucleophilic substitution reaction, phosphoramidate rearrangement and Pechmann cyclization with C-C

  本文报道了在乙醇溶剂中通过碘催化4-溴乙基乙酰乙酸酯，叠氮化钠，亚磷酸三烷基酯和苯酚的一锅四组分反应制备新的香豆素氨基磷酸氨基苯甲酸酯衍生物文库的空前合成途径。该反应通过亲核取代反应，氨基磷酸酯重排和具有CC，CO，CN和NP键形成的Pechmann环化进行。该程序的突出特点是简单的一锅操作，经济高效，无毒且产品收率高。
• [EN] SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS<br/>[FR] OXAZOLES SUBSTITUES ET DERIVES DE THIAZOLES COMME ACTIVATEURS DE ALPHA hPPAR ET DE GAMMA hPPAR
  申请人：GLAXO GROUP LTD

  公开号：WO2000008002A1

  公开（公告）日：2000-02-17

  The present invention discloses compounds of formula (I), and tautomeric forms, pharmaceutically acceptable salts, or solvates thereof. Preferably, the compounds of the invention are dual activators of hPPARη and hPPARα.

  本发明揭示了公式（I）的化合物，以及其互变异构体、药学上可接受的盐或溶剂。优选地，本发明的化合物是hPPARη和hPPARα的双激活剂。
• [EN] PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DU PROLIFERATEUR DES PEROXYSOMES
  申请人：LILLY CO ELI

  公开号：WO2003072100A1

  公开（公告）日：2003-09-04

  The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: (Formula I); wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, aryl (C0-C4) alkyl, aryloxy (C0-C4) alkyl, arylthio (C0-C4) alkyl, and further wherein when R5 is alkyl, R5 can optionally combine with W to form a 6 membered cycloheteroalkyl ring that is fused with the oxazole or thiazole ring to which the R5 group is attached; (b) R9 is selected from the group consisting of C1-C5 alkyl, C1-C5 alkenyl, and arylC0-C3alkyl; (c) T1 is selected from the group consisting of C and N; (d) W is selected from the group consisting of CH2, C(O)N(R21), N(R21), N(R21)CH2, O, OCH2, S, and SO2; and(e) X is selected from the group consisting of C, CH2C, and CCH2.

  本发明涉及以下结构式所表示的化合物及其药学上可接受的盐，公式I：（公式I）;其中：（a）R5选自（C1-C6）烷基，（C1-C6）烯基，芳基（C0-C4）烷基，芳氧基（C0-C4）烷基，芳硫基（C0-C4）烷基，进一步地，当R5是烷基时，R5可以选择与W结合形成一个6元环杂环烷基环，该环与R5基固定的噁唑或噻唑环融合；（b）R9选自C1-C5烷基，C1-C5烯基和芳基C0-C3烷基；（c）T1选自C和N的群；（d）W选自CH2，C（O）N（R21），N（R21），N（R21）CH2，O，OCH2，S和SO2的群；（e）X选自C，CH2C和CCH2的群。